Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPV-06 in inflammatory knee osteoarthritis
2024-514388-24-00Phase 2Authorised
- Sponsor
- Peptinov
- Start
- Dec 2024
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing PPV-06 with Placebo (2 arms). Primary endpoints: Change in WOMAC pain subscale score and Change in WOMAC physical function subscale score. Planned start Dec 2024; status: authorised.
02
Drugs
PPV-06
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2024-514388-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514388-24-00.